OM1 Adds a Half Million Patients to Neurology Network, Strengthening Real-World Evidence Generation and Accelerating Innovation in Neurology

BOSTON--(BUSINESS WIRE)--OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the expansion of its Neurology Specialty Network with the addition of 500,000 patients. The network now includes over 3 million individuals with electronic health records and notes from relevant specialists, making it one of the largest and most clinically rich neurology real-world data resources available.

The expansion significantly enhances OM1’s PremiOM™ datasets in Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, with additional growth in data for other important neurological conditions such as migraine headaches and amyotrophic lateral sclerosis (ALS). These research-ready datasets provide linked, multisource data, including structured and unstructured clinical data, medical and pharmacy claims, and curated outcomes enriched with industry leading AI models, enabling faster and more detailed real-world evidence (RWE) and insights across the neurology care continuum.

“Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” said Dr. Carl Marci, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. “By integrating deep clinical data and advanced AI, we’re equipping researchers and healthcare providers with powerful tools to uncover new insights into disease progression, treatment response, and more personalized care in complex neurological conditions.”

For researchers interested in understanding the neurology patients’ journey across different settings of care, OM1’s neurology network also links to other OM1 specialty networks, such as Primary Care (22M+ patients) and Mental Health (6M+ patients). This captures a more complete view of each patient journey from early symptoms through diagnosis and ongoing treatment, empowering stakeholders to conduct more comprehensive and impactful studies.

According to the World Health Organization, neurological disorders are the leading cause of disability and the second leading cause of death globally, underscoring the urgent need for high-quality real-world data to drive innovation in care and therapeutics.

With its enhanced capabilities, OM1 is uniquely positioned to help life sciences and healthcare organizations accelerate discovery, evidence generation, and personalized medicine in neurology.

About OM1

OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.